Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 523930, 12 pages
http://dx.doi.org/10.1155/2015/523930
Research Article

Nampt/PBEF/Visfatin Upregulation in Colorectal Tumors, Mirrored in Normal Tissue and Whole Blood of Colorectal Cancer Patients, Is Associated with Metastasis, Hypoxia, IL1β, and Anemia

1Department of Gastroenterology and Hepatology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland
2Department of Medical Biochemistry, Wroclaw Medical University, Chalubinskiego 10, 50-368 Wroclaw, Poland
3Department of Gastrointestinal and General Surgery, Wroclaw Medical University, M. Curie-Sklodowskiej 66, 50-369 Wroclaw, Poland
4First Department of Oncological Surgery, Lower Silesian Oncology Center, Plac Hirszfelda 12, 53-413 Wroclaw, Poland
5Wroclaw Research Center EIT+, Stablowicka 147, 54-066 Wroclaw, Poland

Received 5 February 2015; Revised 20 April 2015; Accepted 23 April 2015

Academic Editor: Andreas Jenke

Copyright © 2015 Katarzyna Neubauer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S.-I. Imai, “Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases,” Current Pharmaceutical Design, vol. 15, no. 1, pp. 20–28, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. T.-Q. Bi and X.-M. Che, “Nampt/PBEF/visfatin and cancer,” Cancer Biology & Therapy, vol. 10, no. 2, pp. 119–125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. U. Galli, C. Travelli, A. Massarotti et al., “Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors,” Journal of Medicinal Chemistry, vol. 56, no. 16, pp. 6279–6296, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Pittelli, L. Cavone, A. Lapucci et al., “Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes,” Immunology and Cell Biology, vol. 92, no. 2, pp. 191–199, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. S. E. Hufton, P. T. Moerkerk, R. Brandwijk, A. P. De Bruïne, J.-W. Arends, and H. R. Hoogenboom, “A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization,” FEBS Letters, vol. 463, no. 1-2, pp. 77–82, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. J. R. Van Beijnum, P. T. M. Moerkerk, A. J. Gerbers et al., “Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer,” International Journal of Cancer, vol. 101, no. 2, pp. 118–127, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. T. E. Nakajima, Y. Yamada, T. Hamano et al., “Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer,” Cancer Science, vol. 101, no. 5, pp. 1286–1291, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. S. Fazeli, H. Dashti, S. Akbarzadeh et al., “Circulating levels of novel adipocytokines in patients with colorectal cancer,” Cytokine, vol. 62, no. 1, pp. 81–85, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Chen, Y. Wang, Y. Li et al., “Association of plasma visfatin with risk of colorectal cancer: an observational study of Chinese patients,” Asia-Pacific Journal of Clinical Oncology, 2013. View at Publisher · View at Google Scholar
  10. T. Luk, Z. Malam, and J. C. Marshall, “Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity,” Journal of Leukocyte Biology, vol. 83, no. 4, pp. 804–816, 2008. View at Publisher · View at Google Scholar
  11. M. Krzystek-Korpacka, D. Diakowska, J. Bania, and A. Gamian, “Expression stability of common housekeeping genes is differently affected by bowel inflammation and cancer: implications for finding suitable normalizers for inflammatory bowel disease studies,” Inflammatory Bowel Diseases, vol. 20, no. 7, pp. 1147–1156, 2014. View at Publisher · View at Google Scholar
  12. M. Krzystek-Korpacka, D. Diakowska, B. Kapturkiewicz, M. Bebenek, and A. Gamian, “Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance,” Cancer Letters, vol. 337, no. 1, pp. 107–114, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Vandesompele, K. de Preter, F. Pattyn et al., “Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes,” Genome Biology, vol. 3, no. 7, Article ID RESEARCH0034, 2002. View at Google Scholar · View at Scopus
  14. S. T. Patel, T. Mistry, J. E. P. Brown et al., “A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis,” Peptides, vol. 31, no. 1, pp. 51–57, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Hawthorn, L. Lan, and W. Mojica, “Evidence for field effect cancerization in colorectal cancer,” Genomics, vol. 103, no. 2-3, pp. 211–221, 2014. View at Publisher · View at Google Scholar
  16. C. C. S. Chini, A. M. G. Guerrico, V. Nin et al., “Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors,” Clinical Cancer Research, vol. 20, no. 1, pp. 120–130, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. T.-Q. Bi, X.-M. Che, X.-H. Liao et al., “Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil,” Oncology Reports, vol. 26, no. 5, pp. 1251–1257, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Cerna, H. Li, S. Flaherty, N. Takebe, C. N. Coleman, and S. S. Yoo, “Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner,” The Journal of Biological Chemistry, vol. 287, no. 26, pp. 22408–22417, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Zhang, J. Tong, and G. Huang, “Nicotinamide phosphoribosyl transferase (Nampt) is a target of microRNA-26b in colorectal cancer cells,” PLoS ONE, vol. 8, no. 7, Article ID e69963, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. S. H. Jia, Y. Li, J. Parodo et al., “Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis,” Journal of Clinical Investigation, vol. 113, no. 9, pp. 1318–1327, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Li, Y. Zhang, B. Dorweiler et al., “Extracellular Nampt promotes macrophages survival via a non-enzymatic interleukin-6/ STAT3 signaling mechanism,” The Journal of Biological Chemistry, vol. 283, pp. 34833–34843, 2008. View at Publisher · View at Google Scholar
  22. A. Rongvaux, M. Galli, S. Denanglaire et al., “Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress,” Journal of Immunology, vol. 181, no. 7, pp. 4685–4695, 2008. View at Google Scholar · View at Scopus
  23. K. Neubauer and M. Krzystek-Korpacka, “Visfatin/PBEF/Nampt and other adipocytokines in inflammatory bowel disease,” Advances in Clinical and Experimental Medicine, vol. 19, no. 3, pp. 399–404, 2010. View at Google Scholar
  24. A. R. Moschen, A. Kaser, B. Enrich et al., “Visfatin, an adipocytokine with proinflammatory and immunomodulating properties,” The Journal of Immunology, vol. 178, no. 3, pp. 1748–1758, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Adya, B. K. Tan, A. Punn, J. Chen, and H. S. Randeva, “Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis,” Cardiovascular Research, vol. 78, no. 2, pp. 356–365, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. Y.-H. Bae, M.-K. Bae, S.-R. Kim, J. H. Lee, H.-J. Wee, and S.-K. Bae, “Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis,” Biochemical and Biophysical Research Communications, vol. 379, no. 2, pp. 206–211, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. S.-K. Bae, S.-R. Kim, J. G. Kim et al., “Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1,” FEBS Letters, vol. 580, no. 17, pp. 4105–4113, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Segawa, A. Fukuhara, N. Hosogai et al., “Visfatin in adipocytes is upregulated by hypoxia through HIF1α-dependent mechanism,” Biochemical and Biophysical Research Communications, vol. 349, no. 3, pp. 875–882, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Holen, L. B. Saltz, E. Hollywood, K. Burk, and A.-R. Hanauske, “The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor,” Investigational New Drugs, vol. 26, no. 1, pp. 45–51, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Pirkmajer and A. V. Chibalin, “Serum starvation: caveat emptor,” The American Journal of Physiology—Cell Physiology, vol. 301, no. 2, pp. C272–C279, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Minoo, I. Zlobec, M. Peterson, L. Terracciano, and A. Lugli, “Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles,” International Journal of Oncology, vol. 37, no. 3, pp. 707–718, 2010. View at Google Scholar · View at Scopus
  32. M. Krzystek-Korpacka, D. Diakowska, K. Grabowski, and A. Gamian, “Tumor location determines midkine level and its association with the disease progression in colorectal cancer patients: a pilot study,” International Journal of Colorectal Disease, vol. 27, no. 10, pp. 1319–1324, 2012. View at Publisher · View at Google Scholar · View at Scopus